Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+)
Phase 4
Withdrawn
- Conditions
- Patients With COVID19
- Interventions
- Registration Number
- NCT04351919
- Lead Sponsor
- Abderrahmane Mami Hospital
- Brief Summary
The study will assess the number of patients who become asymptomatic from clinical signs of COVID19 and will assess the efficacy of Hydroxychloroquine (HCQ) and Azithromycine effects on paucisymptomatic patients with ou without co-morbidities
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- confirmed COVID19 (+)
- Qt<500ms
- no severity criteria
- pauci-symptomatique patients
- signed consent form
Exclusion Criteria
- no confirmed patient COVID19
- severity criteria
- known allegies to macrolides and HCQ
- Treated with HCQ within 1 month prior to inclusion
- hepatitis insufficiency
- Renal insufficiency
- treatment no indicated with azithro and HCQ
- hypovolemia
- complete brach block
- retinopathia
- psoriasis
- pregnancy or breastfeeding
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description HCQ Arm Hydroxychloroquine - HCQ Arm Azithromycin -
- Primary Outcome Measures
Name Time Method Evolution of clinical signs at the end of the study treatment - 1 month after inclusion Low respiratory signs with severity criteria
improvment or healing of clinical signs at the end of the study treatment - 1 month after inclusion no respiratory infectious signs
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Eshmoun Clinical Research Centre/ Hôpital Abderrahmen Mami-Ariana
🇹🇳Tunis, Tunisia